Skip to main content
. 2018 May;365(2):249–261. doi: 10.1124/jpet.117.246116

Fig. 5.

Fig. 5.

Total steady-state plasma and brain concentrations (A) and corresponding total steady-state brain-to-plasma ratios (B) of ponatinib after continuous intraperitoneal infusion (40 µg/h) for 48 hours in FVB wild-type, Bcrp1(−/−), Mdr1a/b(−/−), and Mdr1a/b(−/−)Bcrp1(−/−) mice (N = 4 in each genotype) (*P < 0.05; *statistical significance). Data are presented as the mean ± S.D.